McCormick Daniel J, Vlad Tudor, Fasseas Panayotis
Cardiac Catheterization Laboratory, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA.
Perspect Vasc Surg Endovasc Ther. 2007 Sep;19(3):223-7. doi: 10.1177/1531003507304455.
Stroke is the third leading cause of death in the United States. Carotid artery stenosis represents one of the most common etiologies of stroke. The current treatment modalities available for the treatment of carotid artery stenosis are carotid endarterectomy (CEA) and carotid artery stenting (CAS). Several clinical trials comparing CEA with medical management showed superiority of the surgical arm; however, the applicability of these results to the general population is limited by the fact that the patients and surgeons enrolled in these trials were carefully selected, and the optimal medical therapy used does not meet the current treatment standards. Carotid artery stenting has emerged as a treatment alternative to CEA, as shown in randomized trials comparing the 2 treatment modalities. Recent data from large-volume CAS registries indicate that percutaneous treatment of carotid artery stenosis compares favorably to CEA. Furthermore, the CAS trial designs make these results more applicable to the community standards. These data suggest that CAS will become the treatment of choice in patients with carotid artery stenosis.
中风是美国第三大死因。颈动脉狭窄是中风最常见的病因之一。目前可用于治疗颈动脉狭窄的方法有颈动脉内膜切除术(CEA)和颈动脉支架置入术(CAS)。多项比较CEA与药物治疗的临床试验显示手术组具有优势;然而,这些结果在一般人群中的适用性受到限制,因为参与这些试验的患者和外科医生是经过精心挑选的,而且所使用的最佳药物治疗并不符合当前的治疗标准。正如比较这两种治疗方式的随机试验所示,颈动脉支架置入术已成为CEA的替代治疗方法。来自大容量CAS登记处的最新数据表明,经皮治疗颈动脉狭窄与CEA相比具有优势。此外,CAS试验设计使这些结果更适用于社区标准。这些数据表明,CAS将成为颈动脉狭窄患者的首选治疗方法。